Canine Da2Ppv (Orig S-P Us) Lv

Verify with FDA CVM →

363 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
363
Total Reports
66
Deaths Reported
1820.0%
Death Rate

Active Ingredients

Canine Da2Ppv (Orig S-P Us) Lv

Administration Routes

SubcutaneousUnknownIntramuscularSubconjunctival

Species Affected

Dog 363

Most Affected Breeds

Crossbred Canine/dog 92
Retriever - Labrador 24
Chihuahua 20
Shih Tzu 18
Terrier - Yorkshire 16
Shepherd Dog - German 15
Retriever - Golden 13
Spitz - German Pomeranian 10
Pit Bull 9
Boxer (German Boxer) 8

Most Reported Reactions

Vomiting 113
Lethargy (see also Central nervous system depression in 'Neurological') 75
Diarrhoea 66
Emesis (multiple) 55
Death 39
Anorexia 28
Seizure NOS 25
Not eating 24
Death by euthanasia 24
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 22
Other abnormal test result NOS 20
Fever 19

Outcome Breakdown

Recovered/Normal
151 (40.6%)
Ongoing
112 (30.1%)
Died
42 (11.3%)
Outcome Unknown
35 (9.4%)
Euthanized
25 (6.7%)
Recovered with Sequela
7 (1.9%)

Data Summary

Metric Value
Total adverse event reports 363
Reports involving death 66
Case-fatality rate (reported events) 1820.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Canine Da2Ppv (Orig S-P Us) Lv Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 363 adverse event reports referencing Canine Da2Ppv (Orig S-P Us) Lv, including 66 reports in which the animal died — a 1820.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Canine Da2Ppv (Orig S-P Us) Lv. Reported administration routes include Subcutaneous, Unknown, Intramuscular, Subconjunctival. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Canine Da2Ppv (Orig S-P Us) Lv reports are Dog (363 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (92), Retriever - Labrador (24), Chihuahua (20) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Canine Da2Ppv (Orig S-P Us) Lv are Vomiting (113), Lethargy (see also Central nervous system depression in 'Neurological') (75), Diarrhoea (66), Emesis (multiple) (55). Of the 372 reports with a coded outcome, Recovered/Normal is the leading category at 40.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Canine Da2Ppv (Orig S-P Us) Lv.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial